Germany’s cannabis rules face new legal pressure as clubs, doctors and courts collide

Bavaria becomes the next legal battleground for cannabis clubs

The latest confrontation comes from Bavaria, where the Deutscher Hanfverband and CSC Inntal have moved against the state over the refusal of a building-law permit for an cultivation association. According to the association’s own account, the case is meant to force a basic clarification of how such clubs are to be treated under planning and construction rules in the state. The challenge was announced in the DHV’s news update on the lawsuit and in the group’s separate statement on the filing.

The legal dispute matters because it reaches beyond one rejected application. If building-law barriers can be used to block cultivation associations, the practical rollout of the club model becomes far more uncertain. That is especially true in a state that has already taken a hard line on cannabis policy and, by DHV’s account, had signalled opposition before the federal Cannabis Act even came into force.

Medical cannabis is being pulled back toward the doctor’s office

While the club debate plays out in Bavaria, the federal health ministry is pushing a different sort of restriction. Multiple German reports say a draft would require medical cannabis to be prescribed only after personal doctor-patient contact and dispensed only after consultation with a pharmacist, with online prescribing and mail-order access facing tighter limits. The policy shift has been covered by outlets including Apotheken Umschau, Deutschlandfunk, and n-tv.

The ministry’s direction is clear enough: telemedicine-style access, which helped expand the market, is being treated as a problem to be corrected. That is a striking reversal for a market that, by 2025 and early 2026 reporting, had grown sharply under looser prescribing and delivery arrangements. One February 2026 Bloomberg report said imports had surged to an estimated 192 tons in 2025, and a March 2026 GreenState piece described the market as still scaling rapidly.

That growth is one reason the debate has become politically charged. Supporters of tighter rules argue the system has drifted too far from conventional medical practice. Critics say the current evidence points to access and prescription barriers being the real problem. Health Policy Online reported that only about one in ten general practitioners said they would prescribe medical cannabis, while a 2026 survey reported by Cannabis Health News found that more than half of patients said they reduced use of other prescription drugs.

Courts and regulators keep setting the boundaries

The legal picture is not being shaped only by the health ministry. Germany’s top civil court ruled on 26 March 2026 that advertising for medical treatments with cannabis can violate medicinal-products advertising law when it is publicly used to broker prescription treatment. Around the same time, the North Rhine-Westphalia higher administrative court held that a driver’s licence can be immediately revoked if a medical-cannabis patient also regularly consumes unprescribed recreational cannabis. Those decisions do not dismantle legalization, but they do mark out the limits of lawful conduct around it.

There is also a broader institutional unease. In January 2026, Deutsches Ärzteblatt reported broad agreement in Germany that the prescribing framework needs policy changes, while dpa-AFX reporting carried by Onvista said police and doctors’ representatives welcomed a draft tightening medical-cannabis rules. At the same time, the reform remains contested because its effects are mixed: easier access has expanded the legal market, but it has also triggered concern about overuse, advertising, and how to keep medical and non-medical use separate.

The new disputes are less about whether cannabis is legal in principle than about how tightly the system can be boxed in by medical, advertising and zoning rules.

The reform is also being measured against the black market

The political fight is sharpened by competing narratives about whether legalization is working at all. In a March 2026 report, Zeit quoted the federal police chief criticizing the implementation of the Cannabis Act and warning that a large black market still exists in Germany. That concern is echoed by other reporting on enforcement actions, from raids in Hessen and the Berlin region to cases involving illegal plantations and drug-taxi networks in several states.

• In Berlin, the health administration said 208 penalties were lifted after the Cannabis Act.
• A taz report said the administration listed 2,189 cannabis-law offences for the period from April 2025 to February 2026.
• In Hessen, investigators searched against 11 suspects accused of cannabis trading.
• In one Düsseldorf case, more than 6,300 illegal plants were seized in a large gang investigation.

Those figures do not prove one overall trend, but they do show how legalization and enforcement now coexist. The reform has not erased illicit supply, and it has not ended criminal prosecutions tied to the market. Instead, it has created a system in which lawful possession and medical access sit beside a continuing policing effort against trafficking, plantations and organized distribution.

What the first years of legalization have and have not settled

Germany’s adult-use reform is still young enough that every few months brings a new assessment of whether it has delivered what supporters promised or what critics feared. DW’s first-year review in April 2025 found both some support and substantial criticism, while later reporting in 2026 described the law as still failing to settle the debate. The problem is not that the reform disappeared; it is that its partial design left many of the hardest questions unresolved.

That unresolved quality shows up in several places at once. One set of rules expands access through clubs and medical prescribing. Another set of rules tightens oversight through zoning disputes, advertising restrictions and pharmacy-based dispensing. A third set of rules keeps the law under pressure from conservatives who want a rethink after the two-year review, and from officials who argue the illicit market remains too strong. The result is not a single policy direction but a tug-of-war over the meaning of legalization itself.

For readers looking for the larger framework, Cannabivo’s Cannabis Legalization Overview explains how countries tend to split legalization into access, control and enforcement questions. Germany is now living through that split in real time.